Latest Share Chat

IN BRIEF: Diurnal CEO resigns immediately; CFO Bungay interim CEO

Mon, 04th Apr 2022 10:06

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says Martin Whitaker has resigned as chief executive officer and as a member of the board, effective immediately. Chief Financial Officer Richard Bungay acts as interim CEO.

"The board has initiated an international search for a new CEO with strong commercial credentials," the firm adds.

Current stock price: 15.56 pence, down 2.8% on Monday

12-month change: down 80%

By Tom Budszus; tombudszus@alliancenews.com

Related Shares

More News

28 Oct 2022 21:18

TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

21 Oct 2022 21:29

TRADING UPDATES: Trackwise Designs wins deal; Cake Box names CFO

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

14 Oct 2022 15:48

UK shareholder meetings calendar - next 7 days

7 Oct 2022 13:01

Diurnal treatment gets approval from Welsh regulatory body

(Alliance News) - Diurnal Group PLC on Friday said its Efmody treatment has been recommended as an option to treat patients with congenital adrenal hy...

7 Oct 2022 11:31

Diurnal's 'Efmody' treatment gets thumbs-up for NHS Wales

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Friday that the All-Wales Medicines Strategy Group (AWMSG) has recommen...